Page last updated: 2024-09-04

moxifloxacin and AIDS-Related Opportunistic Infections

moxifloxacin has been researched along with AIDS-Related Opportunistic Infections in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chiang, CY; Conradie, F; Dalai, D; Dat, PT; Lan, N; Master, I; Mebrahtu, T; Meredith, SK; Meressa, D; Moodliar, R; Ngubane, N; Nunn, AJ; Phillips, PPJ; Rusen, ID; Sanders, K; Squire, SB; Torrea, G; Tsogt, B; van Deun, A	1
Bonora, S; Calcagno, A; Di Perri, G; Lucchini, A; Mondo, A; Trentini, L	1
Roehr, B	1

Trials

1 trial(s) available for moxifloxacin and AIDS-Related Opportunistic Infections

Article	Year
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. The New England journal of medicine, 2019, 03-28, Volume: 380, Issue:13 Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Moxifloxacin; Rifampin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2019

Article

Year

A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.

The New England journal of medicine, 2019, 03-28, Volume: 380, Issue:13

Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Moxifloxacin; Rifampin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary

2019

Other Studies

2 other study(ies) available for moxifloxacin and AIDS-Related Opportunistic Infections

Article	Year
Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins. The Journal of infection, 2008, Volume: 57, Issue:1 Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Aza Compounds; Contraindications; Drug Resistance, Bacterial; Fluoroquinolones; HIV Infections; Humans; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifamycins; Treatment Outcome; Tuberculosis	2008
Trial tests new combination of drugs to treat tuberculosis. BMJ (Clinical research ed.), 2012, Mar-20, Volume: 344 Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Quinolines; Research Support as Topic; Tuberculosis; United States	2012

Article

Year

Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins.

The Journal of infection, 2008, Volume: 57, Issue:1

Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Aza Compounds; Contraindications; Drug Resistance, Bacterial; Fluoroquinolones; HIV Infections; Humans; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifamycins; Treatment Outcome; Tuberculosis

2008

Trial tests new combination of drugs to treat tuberculosis.

BMJ (Clinical research ed.), 2012, Mar-20, Volume: 344

Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Quinolines; Research Support as Topic; Tuberculosis; United States

2012